Alnylam Pharmaceuticals (ALNY)

Generated: July 25, 2026

Red Dot

Statistics

Metric	Value
Last Close	$205.52
Blended Price Target	327.69
Blended Margin of Safety	59.4% Undervalued
Rule of 40 (Next)	60.3%
Rule of 40 (Current)	81.3%
FCF-ROIC	31.3%
Sales Growth Next Year	29.1%
Sales Growth Current Year	50.0%
Sales 3-Year Avg	57.1%
Industry	Biotechnology

Analysis

Alnylam Pharmaceuticals presents as a high‑quality, but execution‑sensitive, rare‑disease biotech with a distinctive platform and a rapidly scaling commercial franchise. Its transition from a development‑stage RNA interference pioneer to a multi‑product revenue business is well underway, anchored by the transthyretin‑mediated amyloidosis (TTR) portfolio and supported by a smaller rare‑disease franchise.^[1] The recent step‑change in quarterly revenues and 2026 guidance indicate a company entering a more mature, growth‑and‑profitability balancing phase rather than a binary pipeline story.^[1]^[2]

Revenue growth visibility is unusually high for a biotech, driven by chronic therapies in diseases with long treatment duration and a growing diagnosed patient base, but still exposed to payer dynamics and competitive innovation.^[1]^[2] The economic moat rests on deep RNAi know‑how, first‑mover regulatory positions, and a broad clinical pipeline, though small‑molecule, gene‑editing, and competing RNA modalities are credible long‑term threats. Leadership appears strategically bold and commercially capable, as reflected in the “Alnylam 2030” plan and aggressive revenue targets, but must prove it can sustain innovation while managing margin pressure and reimbursement scrutiny over time.^[2]^[6]

What the Company Does

Alnylam develops and commercializes RNA interference (RNAi) therapeutics that silence disease‑causing genes, primarily for rare, serious conditions.^[6] Its approved drugs include AMVUTTRA and ONPATTRO for TTR amyloidosis, and GIVLAARI and OXLUMO for rare metabolic and renal disorders.^[1] It earns money mainly by selling these branded prescription medicines globally, supplemented by collaboration and royalty income from partners, although recent communications emphasize product revenues as the core engine.^[1]^[2]

The business is currently dominated by the TTR franchise, where AMVUTTRA has become the primary growth driver and ONPATTRO an additional revenue contributor.^[1] A smaller but meaningful portion comes from the “Rare” franchise, comprising GIVLAARI and OXLUMO.^[1]^[2] In Q1 2026, management highlighted that TTR products generated the vast majority of net product revenue, with the Rare portfolio contributing a modest but growing share.^[1] The mix is therefore concentrated, with a single therapeutic area accounting for most commercial performance.

Revenue Recurrence & Predictability

Alnylam’s revenues are largely chronic therapy sales rather than one‑time procedures, meaning patients typically remain on treatment for extended periods and prescriptions recur, subject to adherence and payer decisions.^[1] This structure gives the company a base of semi‑recurring revenue, especially in established patient cohorts, although it does not have subscription contracts in the software sense. Demand is driven by ongoing diagnosis of new patients plus retention of existing ones on therapy.^[1]

Predictability is further supported by the rarity and severity of the conditions treated, where alternatives are limited and discontinuation risks are more medical than discretionary.^[6] However, revenues remain exposed to formulary changes, reimbursement negotiations, competitive entries, and potential shifts toward earlier‑line use or gene‑editing approaches. Overall, Alnylam enjoys reasonably high revenue visibility over a multi‑year horizon, but with the inherent volatility of a concentrated, high‑priced specialty pharma portfolio.

Revenue Growth Durability

Alnylam’s above‑market revenue growth is currently underpinned by rapid penetration of the ATTR cardiomyopathy opportunity through AMVUTTRA, where management and analysts expect strong expansion through at least the late 2020s.^[2]^[6] The company’s 2026 combined net product revenue guidance of $4.9–$5.3 billion, implying robust growth from 2025, signals confidence in continued uptake in both existing and newly diagnosed patients.^[2]^[3] This suggests several years of high‑teens or better revenue growth remain plausible, assuming continued execution.

Longer‑term durability hinges on expanding the RNAi platform into additional indications and geographies, while maintaining share in TTR against potential competing modalities. Structural tailwinds include better disease awareness, improved genetic testing, and aging populations driving cardiomyopathy prevalence.^[6] Headwinds include eventual market saturation in core TTR segments, potential price pressures, and the need to refresh the portfolio with new launches as patent cliffs approach. Growth should remain above typical pharma averages for some time, but will likely moderate as the current wave of TTR expansion matures.

Economic Moat

Alnylam’s moat is primarily an intangible‑asset and know‑how moat built around decades of RNAi science, clinical data, and regulatory experience.^[6] It holds multiple approved RNAi drugs, a broad pipeline, and manufacturing capabilities tailored to this modality, creating barriers for late‑comers. Its first‑mover advantage in TTR and selected rare diseases also yields embedded physician familiarity and treatment algorithms that are not easily displaced.^[1]^[2]

Switching costs for individual patients can be meaningful due to clinical stability on therapy and physician comfort, although they are not absolute; future entrants could offer more convenient dosing or curative profiles. Cost advantages are less visible than scientific and regulatory ones, and there are no classic network effects. The moat appears to be widening for now as AMVUTTRA’s commercial success and the “Alnylam 2030” strategy reinforce its leadership in RNAi, but competitive pressure from other genetic and RNA‑based approaches will test the durability of that edge over the next decade.^[2]^[6]

Management & Leadership

Alnylam is no longer founder‑led in the day‑to‑day operational sense, but its leadership retains continuity with the company’s scientific roots. The current management team has overseen the transition from a primarily R&D‑focused organization to a commercial enterprise, including the launch and scaling of AMVUTTRA and the broader TTR franchise.^[1]^[2] The introduction of the “Alnylam 2030” strategy reflects a willingness to commit publicly to ambitious, multi‑year goals.^[2]

Recent communications emphasize disciplined investment in R&D alongside margin improvement, suggesting a management philosophy focused on long‑term platform value rather than near‑term profitability maximization.^[2]^[6] Detailed, up‑to‑date insider ownership figures are not clearly disclosed in the sources available within the last six months, but the tone of guidance and pipeline investment signals alignment with continued growth and innovation. Capital allocation has centered on funding clinical programs and commercial expansion rather than aggressive financial engineering.^[2]^[6]

Key Risks

The most immediate business risk is concentration risk in the TTR franchise. A large share of revenues now depend on AMVUTTRA and ONPATTRO, particularly in ATTR cardiomyopathy.^[1] Any safety signal, reimbursement pushback, or superior competitor could disproportionately impact the company’s financial profile. This is amplified by the ambitious revenue guidance that assumes sustained strong uptake, giving less margin for error.^[2]^[3]

Alnylam also faces competitive and technological risk. RNAi is just one modality in a rapidly evolving genetic medicine landscape that includes gene editing, gene therapy, antisense oligonucleotides, and small‑molecule approaches.^[6] Future therapies offering functional cures or simpler administration could erode the appeal of chronic RNAi treatments. Maintaining a moat will require continuous innovation and successful pipeline execution, not just defending current indications.

Finally, regulatory and pricing risk is material. Alnylam’s drugs are high‑cost specialty therapies for rare diseases, and global payers are increasingly scrutinizing budget impact and cost‑effectiveness.^[6] As volumes grow and total franchise revenues climb, the therapies may attract more attention from health authorities and insurers, potentially pressuring prices or access terms. Operationally, scaling manufacturing and global distribution for complex RNA therapeutics also carries execution and supply‑chain risks, though recent results suggest the company has managed early scaling effectively.^[1]

Sources

Featured in GreenDot Stocks Analysis

GreenDot Stocks Screen Update — Week of July 25, 2026 July 25, 2026
GreenDot Stocks Screen Update — Week of July 17, 2026 July 17, 2026
GreenDot Stocks Screen Update — Week of July 11, 2026 July 11, 2026
GreenDot Stocks Screen Update — Week of July 4, 2026 July 4, 2026
GreenDot Stocks Screen Update — Week of June 27, 2026 June 27, 2026